Jiang Xian, Lai Wei, Gao Xinghua, Zeng Weihui, Tao Juan, Li Yuzhen, Yu Nan, Li Ji, Lu Qianjin, Xiao Rong, Xiong Ying, Yang Jie, Zhang Litao, Chen Jin, Chen Xu-E, Sun Nana, Tao Shiqin, Xu Nan, Zhou Yongan, Ye Juan, Zhang Fan, Yang Enpin
Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Clin Exp Dermatol. 2025 Jul 24. doi: 10.1093/ced/llaf316.
Rosacea is a chronic inflammatory skin disorder with a complex etiology involving genetic, immunological, and environmental factors. Despite various treatments, managing papulopustular lesions remains challenging. Salicylic acid, known for its anti-inflammatory properties, has been used in dermatology for decades, but its efficacy in treating rosacea needs further exploration. This study investigated the effectiveness and safety of 30% supramolecular salicylic acid (SSA) in treating papulopustular rosacea.
We conducted a prospective, multicenter, randomized, double-blind, placebo-controlled trial involving 480 patients aged 18 to 60 years with papulopustular rosacea. Participants were randomized 1:1 to receive either 30% SSA or placebo biweekly for six weeks, with follow-up assessments up to week 8. The study assessed primary and secondary efficacy endpoints, including lesion reduction rates, IGA and ISA scores, VISIA red area improvements, and skin barrier functions, as well as safety and tolerability evaluations.
The SSA group showed a significant improvement in the primary efficacy endpoint at week 8, with efficacy rates of 51.25% (full-analysis set, FAS) and 59.90% (per-protocol set, PPS), compared to 18.33% (FAS) and 20.50% (PPS) in the placebo group (P<0.0001 for both). Secondary endpoints also favored SSA, demonstrating notable improvements in lesion reduction, IGA and ISA scores, and skin condition. Safety profiles were comparable between the SSA and placebo groups, with no significant difference in adverse event rates.
The study's findings highlight the superior efficacy of 30% SSA in improving papulopustular rosacea symptoms compared with that of a placebo, coupled with a favorable safety and tolerability profile. Although the multicenter design and rigorous methodology strengthen the validity of the study, limitations such as short-term follow-up and potential site variability warrant consideration. Further long-term studies are recommended to fully ascertain the therapeutic potential of SSA in rosacea treatment.
